Business

Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder Letter

Accelerating Demand Driving Strong Revenue Growth Vancouver, British Columbia--(Newsfile Corp. -...

articleBurcon Nutrascience CorporationDecember 15, 20255/company/burcon-nutrascience-corporation/news/burcon-highlights-strong-year-of-execution-and-commercial-momentum-in-shareholder-letter
Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder Letter

About this update from Burcon Nutrascience Corporation

[{"type":"text","content":"Burcon Highlights Strong Year of Execution and Commercial Momentum in Shareholder LetterAccelerating Demand Driving Strong Revenue GrowthVancouver, British Columbia--(Newsfile Corp. - December 15, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (\"Burcon\" or the \"Company\"), a global technology leader in plant-based protein innovation, is pleased to issue a letter to shareholders from its Chief Executive Officer, Kip Underwood.Dear Fellow Shareholders,2025 was a transformational year for Burcon, marking the beginning of an exciting phase of growth as we build on our commercial momentum heading into 2026. I can say with confidence that Burcon has never been in a stronger position than it is today. Our achievements in commercial execution, manufacturing, and technology validation have positioned us for meaningful growth as we advance into the next phase of our commercialization journey.Commercial Momentum and Sales GrowthIn recent months, we have seen customers progress from evaluation to commercial purchase orders, driven by our clear product differentiation-high purity, clean taste, and functionality across multiple food and beverage applications.Today, we are generating ingredient sales across our pea, canola, and fava protein platforms, with calendar 2025 revenue expected to be in the range of $1-3 million. Recent customer activity and expanding purchase commitments reflect strong market adoption and are translating into increasing revenue. Building on this momentum, we reaffirm our revenue target of more than $10 million for calendar 2026.Proven Protein Technology PlatformThrough our strategic manufacturing partnership with RE ProMan LLC, we continue to advance the commercial deployment of Burcon's protein technology platform, enabling scalable, reliable production to meet growing customer demand across multiple protein categories.A major achievement this year was the successful validation of our patented protein technologies at full commercial scale. This accomplishment significantly reduces technology and execution risk and confirms Burcon's ability to consistently deliver high-performance protein ingredients into large and rapidly expanding food and nutrition markets.Industry Demand Aligned with Burcon's StrengthsFood and beverage manufacturers are increasingly looking for clean-label, better-tastin...

More updates from Burcon Nutrascience Corporation